HomeBUSINESS
BUSINESS

Tagrisso Significantly Extends PFS in Japanese EGFRm NSCLC Patients
(Oct.17.2017)

AstraZeneca’s EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) significantly prolonged progression-free survival (PFS) in Japanese patients with EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), the company’s Japan unit said on October 16 ...
(LOG IN FOR FULL STORY)

News Calendar